DrugPatentWatch Database Preview
Patent: 8,247,397
» See Plans and Pricing
Summary for Patent: 8,247,397
| Title: | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| Abstract: | Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001## |
| Inventor(s): | Belvin; Marcia (South San Francisco, CA), Friedman; Lori (South San Francisco, CA), Hoeflich; Klaus (San Mateo, CA), Sampath; Deepak (San Francisco, CA), Vijapurkar; Ulka (Millbrae, CA), Wallin; Jeffrey (Berkeley, CA), Johnson; Leisa (Point Richmond, CA), Singh; Mallika (San Francisco, CA), Patel; Sonal (Slough, GB) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) |
| Application Number: | 12/208,227 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,247,397
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,247,397
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201002475 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009036082 | Start Trial |
| United States of America | 2009098135 | Start Trial |
| United States of America | 2011223619 | Start Trial |
| United States of America | 2013345217 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
